NO822995L - Ny lipidfraksjon, dens fremstilling og farmasoeytisk preparater inneholdende fraksjonen - Google Patents

Ny lipidfraksjon, dens fremstilling og farmasoeytisk preparater inneholdende fraksjonen

Info

Publication number: NO822995L
Authority: NO; Norway
Prior art keywords: lipid; preparation according; fraction; weight; preparation
Prior art date: 1981-09-04

Application number

NO822995A

Other languages

English (en)

Norwegian (no)

Inventor

Meir Shinitzky

David Heron

David Samuel

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-09-04

Filing date

1982-09-03

Publication date

1983-03-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11052892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO822995(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1982-09-03 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

1983-03-07 Publication of NO822995L publication Critical patent/NO822995L/no

Links

150000002632 lipids Chemical class 0.000 title claims description 73
238000002360 preparation method Methods 0.000 title claims description 28
239000000825 pharmaceutical preparation Substances 0.000 title claims description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 62
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 18
238000011282 treatment Methods 0.000 claims description 18
238000000034 method Methods 0.000 claims description 16
150000003904 phospholipids Chemical class 0.000 claims description 16
239000002244 precipitate Substances 0.000 claims description 15
102000002322 Egg Proteins Human genes 0.000 claims description 14
108010000912 Egg Proteins Proteins 0.000 claims description 14
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
235000013345 egg yolk Nutrition 0.000 claims description 14
210000002969 egg yolk Anatomy 0.000 claims description 14
239000007788 liquid Substances 0.000 claims description 14
239000000203 mixture Substances 0.000 claims description 14
239000003963 antioxidant agent Substances 0.000 claims description 12
230000003078 antioxidant effect Effects 0.000 claims description 12
238000000338 in vitro Methods 0.000 claims description 11
229930003799 tocopherol Natural products 0.000 claims description 8
229960001295 tocopherol Drugs 0.000 claims description 8
239000011732 tocopherol Substances 0.000 claims description 8
235000010384 tocopherol Nutrition 0.000 claims description 8
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
235000012000 cholesterol Nutrition 0.000 claims description 7
239000000284 extract Substances 0.000 claims description 7
238000001704 evaporation Methods 0.000 claims description 6
238000001556 precipitation Methods 0.000 claims description 5
239000000725 suspension Substances 0.000 claims description 5
230000008020 evaporation Effects 0.000 claims description 4
125000005456 glyceride group Chemical group 0.000 claims description 4
244000068988 Glycine max Species 0.000 claims description 3
235000010469 Glycine max Nutrition 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 3
238000000605 extraction Methods 0.000 claims description 3
238000010253 intravenous injection Methods 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
238000011084 recovery Methods 0.000 claims description 3
239000007858 starting material Substances 0.000 claims description 3
244000046052 Phaseolus vulgaris Species 0.000 claims description 2
235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 2
239000000654 additive Substances 0.000 claims 4
230000000996 additive effect Effects 0.000 claims 4
235000003441 saturated fatty acids Nutrition 0.000 claims 3
150000004671 saturated fatty acids Chemical class 0.000 claims 3
235000021122 unsaturated fatty acids Nutrition 0.000 claims 3
150000004670 unsaturated fatty acids Chemical class 0.000 claims 3
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 2
239000002552 dosage form Substances 0.000 claims 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
150000008104 phosphatidylethanolamines Chemical class 0.000 claims 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
239000005642 Oleic acid Substances 0.000 claims 1
235000021314 Palmitic acid Nutrition 0.000 claims 1
235000021355 Stearic acid Nutrition 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
229940114079 arachidonic acid Drugs 0.000 claims 1
235000021342 arachidonic acid Nutrition 0.000 claims 1
235000014113 dietary fatty acids Nutrition 0.000 claims 1
229930195729 fatty acid Natural products 0.000 claims 1
239000000194 fatty acid Substances 0.000 claims 1
150000004665 fatty acids Chemical class 0.000 claims 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
235000020778 linoleic acid Nutrition 0.000 claims 1
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
239000008117 stearic acid Substances 0.000 claims 1
239000012528 membrane Substances 0.000 description 29
241001465754 Metazoa Species 0.000 description 18
230000000694 effects Effects 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 14
210000004556 brain Anatomy 0.000 description 11
238000005243 fluidization Methods 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000008280 blood Substances 0.000 description 9
239000002904 solvent Substances 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
235000005911 diet Nutrition 0.000 description 8
230000037213 diet Effects 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
229960005181 morphine Drugs 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
206010020772 Hypertension Diseases 0.000 description 6
241000700159 Rattus Species 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
229930003427 Vitamin E Natural products 0.000 description 5
230000032683 aging Effects 0.000 description 5
235000006708 antioxidants Nutrition 0.000 description 5
230000007547 defect Effects 0.000 description 5
230000007812 deficiency Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
230000006870 function Effects 0.000 description 5
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
239000011709 vitamin E Substances 0.000 description 5
235000019165 vitamin E Nutrition 0.000 description 5
229940046009 vitamin E Drugs 0.000 description 5
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 4
208000007848 Alcoholism Diseases 0.000 description 4
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
238000005194 fractionation Methods 0.000 description 4
230000001771 impaired effect Effects 0.000 description 4
239000002858 neurotransmitter agent Substances 0.000 description 4
FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 4
238000011160 research Methods 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
201000001320 Atherosclerosis Diseases 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
208000008589 Obesity Diseases 0.000 description 3
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
244000258044 Solanum gilo Species 0.000 description 3
206010044565 Tremor Diseases 0.000 description 3
201000001883 cholelithiasis Diseases 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
230000004064 dysfunction Effects 0.000 description 3
235000013601 eggs Nutrition 0.000 description 3
238000001914 filtration Methods 0.000 description 3
208000001130 gallstones Diseases 0.000 description 3
230000001631 hypertensive effect Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
208000000509 infertility Diseases 0.000 description 3
230000036512 infertility Effects 0.000 description 3
231100000535 infertility Toxicity 0.000 description 3
229940067606 lecithin Drugs 0.000 description 3
239000000787 lecithin Substances 0.000 description 3
235000010445 lecithin Nutrition 0.000 description 3
230000003340 mental effect Effects 0.000 description 3
235000020824 obesity Nutrition 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
229910052698 phosphorus Inorganic materials 0.000 description 3
239000011574 phosphorus Substances 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
230000008569 process Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
210000002182 synaptic membrane Anatomy 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000012546 transfer Methods 0.000 description 3
230000007704 transition Effects 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
BOBLSBAZCVBABY-WPWUJOAOSA-N 1,6-diphenylhexatriene Chemical compound C=1C=CC=CC=1\C=C\C=C\C=C\C1=CC=CC=C1 BOBLSBAZCVBABY-WPWUJOAOSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
206010003591 Ataxia Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
208000036626 Mental retardation Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
208000027089 Parkinsonian disease Diseases 0.000 description 2
206010034010 Parkinsonism Diseases 0.000 description 2
206010043118 Tardive Dyskinesia Diseases 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
229960004373 acetylcholine Drugs 0.000 description 2
230000006978 adaptation Effects 0.000 description 2
201000007930 alcohol dependence Diseases 0.000 description 2
230000007815 allergy Effects 0.000 description 2
210000001638 cerebellum Anatomy 0.000 description 2
230000007882 cirrhosis Effects 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
238000011109 contamination Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
206010013663 drug dependence Diseases 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
230000008747 mitogenic response Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
229960004127 naloxone Drugs 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
238000001243 protein synthesis Methods 0.000 description 2
230000003716 rejuvenation Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
210000003705 ribosome Anatomy 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
201000000980 schizophrenia Diseases 0.000 description 2
230000009758 senescence Effects 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000007787 solid Substances 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
230000014616 translation Effects 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
201000006347 Intellectual Disability Diseases 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010033546 Pallor Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
229930003316 Vitamin D Natural products 0.000 description 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
208000029650 alcohol withdrawal Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940025084 amphetamine Drugs 0.000 description 1
230000002547 anomalous effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
DDPMGIMJSRUULN-UHFFFAOYSA-N buphedrone Chemical compound CCC(NC)C(=O)C1=CC=CC=C1 DDPMGIMJSRUULN-UHFFFAOYSA-N 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
230000035558 fertility Effects 0.000 description 1
238000002875 fluorescence polarization Methods 0.000 description 1
230000037406 food intake Effects 0.000 description 1
210000004744 fore-foot Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
239000007970 homogeneous dispersion Substances 0.000 description 1
230000036737 immune function Effects 0.000 description 1
230000008076 immune mechanism Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
230000003859 lipid peroxidation Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
-1 phospho-'lipisacyl chains Chemical group 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
210000004129 prosencephalon Anatomy 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000009822 protein phosphorylation Effects 0.000 description 1
230000007363 regulatory process Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
208000026775 severe diarrhea Diseases 0.000 description 1
239000010802 sludge Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000003351 stiffener Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
229940042585 tocopherol acetate Drugs 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000005945 translocation Effects 0.000 description 1
235000019166 vitamin D Nutrition 0.000 description 1
239000011710 vitamin D Substances 0.000 description 1
150000003710 vitamin D derivatives Chemical class 0.000 description 1
229940046008 vitamin d Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B3/00—Refining fats or fatty oils
- C11B3/006—Refining fats or fatty oils by extraction

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Immunology (AREA)
Virology (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO822995A 1981-09-04 1982-09-03 Ny lipidfraksjon, dens fremstilling og farmasoeytisk preparater inneholdende fraksjonen NO822995L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IL63734A IL63734A (en)	1981-09-04	1981-09-04	Lipid fraction,its preparation and pharmaceutical compositions containing same

Publications (1)

Publication Number	Publication Date
NO822995L true NO822995L (no)	1983-03-07

Family

ID=11052892

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO822995A NO822995L (no)	1981-09-04	1982-09-03	Ny lipidfraksjon, dens fremstilling og farmasoeytisk preparater inneholdende fraksjonen

Country Status (8)

Country	Link
US (1)	US4474773A (de)
EP (1)	EP0074251B2 (de)
JP (1)	JPH0786088B2 (de)
AU (1)	AU555915B2 (de)
DE (1)	DE3262884D1 (de)
FI (1)	FI75270C (de)
IL (1)	IL63734A (de)
NO (1)	NO822995L (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5925328A (ja) *	1982-07-29	1984-02-09	Ajinomoto Co Inc	コレステロ−ル低下又は上昇抑制作用を有する組成物
JPS6097916A (ja) *	1983-11-01	1985-05-31	Ajinomoto Co Inc	コレステロ−ル低下又は上昇抑制作用を有する組成物
IL71051A (en) *	1984-02-23	1988-02-29	Yeda Res & Dev	Compositions containing active lipids for the treatment of cystic fibrosis
US4678807A (en) *	1984-03-01	1987-07-07	Baxter Travenol Laboratories, Inc.	Method for directed visceral metabolism of medium chain triglycerides
AU594066B2 (en) *	1985-07-26	1990-03-01	Yeda Research And Development Co. Ltd.	A special lipid mixture for membrane fluidization
US4857514A (en) *	1985-09-17	1989-08-15	Yeda Research And Development Company, Ltd.	Virus inactivation
DE3600664A1 (de) *	1986-01-13	1987-07-16	Nattermann A & Cie	Pflanzenbehandlungsmittel
US4812314A (en) *	1986-02-24	1989-03-14	Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization	Lipid replacement therapy
US5599840A (en) *	1986-11-26	1997-02-04	Bar Ilan University	Physiologically active and nutritional composition
US5260284A (en) *	1987-02-17	1993-11-09	Board Of Regents, The University Of Texas System	Methods employing unique mixtures of polar and neutral lipids and sterol for lung surfactant replacement therapy
US5032585A (en) *	1987-02-17	1991-07-16	Board Of Regents, The University Of Texas System	Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy
US5043329A (en) *	1987-02-17	1991-08-27	Board Of Regents, University Of Texas System	Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US4918063A (en) *	1987-02-17	1990-04-17	Board Of Regents, The University Of Texas System	Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
JP2732056B2 (ja) *	1987-10-01	1998-03-25	仙味エキス株式会社	降圧並びに血管拡張剤
IL84840A0 (en) *	1987-12-16	1988-06-30	Rapaport Erich	Dietary supplement
US20060094089A1 (en) *	1988-09-07	2006-05-04	Martek Biosciences Corporation	Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids
US5340742A (en) *	1988-09-07	1994-08-23	Omegatech Inc.	Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US4981844A (en) *	1988-10-04	1991-01-01	University Of Cincinnati	Method to improve immune response and resistance to infection following surgery by diet composition
US5055446A (en) *	1988-10-21	1991-10-08	University Of Cincinnati	Method to improve survival of patients during sepsis by diet composition
IL91802A (en) *	1988-10-27	1994-05-30	Univ Bar Ilan	Preparations containing linoleic acid history for the treatment of Alzheimer's, similar brain diseases, and epilepsy
DE68903930T2 (de) *	1988-11-23	1993-05-19	Abbott Lab	Lipidemulsion zur behandlung von aids.
US5368712A (en) *	1989-11-02	1994-11-29	Synporin Technologies, Inc.	Biologically mimetic synthetic ion channel transducers
DE4017979A1 (de) *	1990-06-05	1991-12-12	Meyer Lucas Gmbh & Co	Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen
FR2683721B1 (fr) *	1991-11-15	1995-06-09	Inocosm Laboratoires	Composition lipidique polaire permettant de vehiculer un agent actif et/ou de le faire penetrer dans une cellule cible.
US5319116A (en) *	1992-02-12	1994-06-07	Gary Viole	Lecithin fractions and dilutions, methods for their preparation and pharmacological uses thereof
WO1994003192A1 (en) *	1992-07-29	1994-02-17	Drymed A/S	Composition comprising fertilized shell eggs
US5674855A (en) *	1992-08-12	1997-10-07	The Rogosin Institute	Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
DE4407917C2 (de) *	1993-03-15	2002-12-12	Sueddeutsche Kalkstickstoff	Verfahren zur Gewinnung von Lipidfraktionen aus pulverförmigen Eiprodukten
BR9508584B8 (pt) *	1994-08-10	2014-11-18	Sepsicure L L C	Composição farmacêutica isenta de peptídeo e proteína e adequada para administração intravenosa
US20080175953A1 (en) *	1995-06-07	2008-07-24	Martek Biosciences Corporation	Process for the Heterotrophic Production of Microbial Products with High Concentrations of Omega-3 Highly Unsaturated Fatty Acids
IL114458A0 (en) *	1995-07-05	1995-11-27	Yeda Res & Dev	Therapeutic preparations for treatment of T cell mediated diseases
US20030190323A1 (en) *	1995-07-05	2003-10-09	Yeda Research And Development Co. Ltd.	Preparations and methods for the treatment of T cell mediated diseases
US6488933B2 (en)	1995-07-05	2002-12-03	Yeda Research And Development Co. Ltd.	Preparations for the treatment of T cell mediated diseases
US5718917A (en) *	1995-12-15	1998-02-17	Harvard Scientific Corporation	PGE-1 containing lyophilized liposomes for use in the treatment of erectile dysfunction
US6015576A (en) *	1997-08-29	2000-01-18	Bio-Sphere Technology, Inc.	Method for inducing a systemic immune response to an antigen
US6117449A (en) *	1996-03-22	2000-09-12	Bio-Sphere Technology, Inc.	Method for inducing a systemic immune response to a hepatitis antigen
US6207185B1 (en)	1996-03-22	2001-03-27	Bio-Sphere Technology	Method for inducing a systemic immune response to an HIV antigen
NO303819B1 (no) *	1996-11-20	1998-09-07	Drymed As	Anvendelse av t°rkede, fertiliserte h°nse-egg for fremstilling av anti-depressive midler
US20010003580A1 (en) *	1998-01-14	2001-06-14	Poh K. Hui	Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
DE19909115A1 (de) *	1999-03-03	2000-09-07	Florian Lang	Verwendung von Ceramiden zur Behandlung cystischer Fibrose
US7947737B1 (en) *	1999-09-30	2011-05-24	Aker Biomarine Asa	Method of treating hypertension and reducing serum lipase activity
EP2960325B1 (de)	2000-01-28	2017-09-27	DSM IP Assets B.V.	Verstärkte produktion von lipiden enthaltend mehrfach ungesaettigte fettsaeuren durch hochdichte kulturen von eukaryotischen mikroorganismen in fermentoren
US6733797B1 (en) *	2000-11-15	2004-05-11	William K. Summers	Neuroceutical for improving memory and cognitive abilities
WO2003009704A2 (en) *	2001-07-27	2003-02-06	N.V. Nutricia	Enteral compositions for the prevention and/or treatment of sepsis
WO2007108695A1 (en) *	2006-03-22	2007-09-27	Memoran As	Preparation for prophylactic or therapeutic treatment of lapse of memory
EP2073822A4 (de) *	2006-10-12	2010-04-14	United Paragon Associates Inc	Verfahren zur herstellung gedüngter komponenten von eiern
WO2010118362A1 (en)	2009-04-09	2010-10-14	The Regents Of The University Of Colorado, A Body Corporate	Methods and compositions for inducing physiological hypertrophy
JP6166480B2 (ja) *	2013-12-11	2017-07-19	ヘルス−エバーバイオテックカンパニーリミテッド	カロテノイドの医薬組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2390528A (en) *	1940-05-13	1945-12-11	Pittsburgh Plate Glass Co	Extraction of phosphatides, free fatty acids, and the like from glyceride oils
FR1170215A (fr) *	1956-11-17	1959-01-12		Perfectionnements apportés aux procédés d'extraction de lipides à partir de matières premières diverses
GB933814A (en) *	1959-05-12	1963-08-14	Unilever Ltd	Improvements in or relating to the purification of phosphatides
US3752832A (en) *	1970-09-08	1973-08-14	Kongo Yakuhin K K	Process for anti oxidation against lipid
JPS54117034A (en) *	1978-02-28	1979-09-11	Nippon Shoji Kk	Treating agent for consciousness and perception motion disorder
US4157404A (en) *	1978-07-28	1979-06-05	Asahi Kasei Kogyo Kabushiki Kaisha	Process for obtaining yolk lecithin from raw egg yolk
GB2046092B (en) *	1979-03-05	1983-11-02	Toyama Chemical Co Ltd	Pharmaceutical composition containing a lysophospholid and a phospholipid
US4221784A (en) *	1979-04-05	1980-09-09	Massachusetts Institute Of Technology	Process and composition for treating disorders by administering lecithin
US4254115A (en) *	1979-06-18	1981-03-03	A. Nattermann & Cie. Gmbh	Phospholipid derivative with an antilipemic and antiarteriosclerotic effect

1981
- 1981-09-04 IL IL63734A patent/IL63734A/xx not_active IP Right Cessation
1982
- 1982-05-13 US US06/377,959 patent/US4474773A/en not_active Expired - Lifetime
- 1982-08-27 AU AU87782/82A patent/AU555915B2/en not_active Ceased
- 1982-09-01 FI FI823013A patent/FI75270C/fi not_active IP Right Cessation
- 1982-09-02 EP EP82304626A patent/EP0074251B2/de not_active Expired - Lifetime
- 1982-09-02 DE DE8282304626T patent/DE3262884D1/de not_active Expired
- 1982-09-03 NO NO822995A patent/NO822995L/no unknown
- 1982-09-03 JP JP57153788A patent/JPH0786088B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0074251B2 (de)	1991-01-30
JPH0786088B2 (ja)	1995-09-20
FI75270B (fi)	1988-02-29
JPS58126812A (ja)	1983-07-28
AU8778282A (en)	1983-03-10
FI75270C (fi)	1988-06-09
IL63734A (en)	1985-07-31
EP0074251A1 (de)	1983-03-16
EP0074251B1 (de)	1985-04-03
FI823013L (fi)	1983-03-05
IL63734A0 (en)	1981-12-31
US4474773A (en)	1984-10-02
FI823013A0 (fi)	1982-09-01
AU555915B2 (en)	1986-10-16
DE3262884D1 (en)	1985-05-09

Publication	Publication Date	Title
NO822995L (no)	1983-03-07	Ny lipidfraksjon, dens fremstilling og farmasoeytisk preparater inneholdende fraksjonen
KR101787618B1 (ko)	2017-10-18	항중추신경계 염증제
JP3053537B2 (ja)	2000-06-19	脳機能改善剤
US4677099A (en)	1987-06-30	Medical processes employing a novel lipid fraction
KR20120114335A (ko)	2012-10-16	뇌신경 세포 신생제
EP3095451A1 (de)	2016-11-23	Prozess zur zubereitung eines tierischen gehirnextraktes
CN107001980A (zh)	2017-08-01	醚磷脂及其制备方法
JPS6284028A (ja)	1987-04-17	膜流動化のための脂質混合物
CA2035951C (en)	2001-07-31	Bilobalide derivatives, their applications and formulations containing them
Allen et al.	1933	The quantitative separation of progestin from oestrin in extracts of the corpus luteum
CLARKE et al.	1970	Interrelationships between plasma lipids, physical measurements, and body fatness of adolescents in Burlington, Vermont
JP2002535281A (ja)	2002-10-22	接着分子の発現を調節することができる薬剤組成物
FR2823116A1 (fr)	2002-10-11	Procede de preparation d'une extrait de feuilles de ginkgo biloba hautement enrichi en principes actifs
JP2005515969A (ja)	2005-06-02	ビタミン貯蔵の調節
AU2014202925B2 (en)	2015-07-09	Chewable wafers containing lipid supplements for maintaining health and the treatment of acute and chronic disorders
US4843092A (en)	1989-06-27	Immunosuppressive agent
WO1994018949A1 (en)	1994-09-01	Lecithin fractions and dilutions, methods for their preparation and pharmacological uses thereof
CA1251782A (en)	1989-03-28	Lipid fraction, its preparation and pharmaceutical compositions containing same
PL82013B1 (en)	1975-10-31	New hormone[au4483972a]
US20090022757A1 (en)	2009-01-22	Method for treating photoreceptor cell degeneration
US2202307A (en)	1940-05-28	Vitamin concentration
WO2016072710A1 (ko)	2016-05-12	세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 신경안정용 조성물
GB2316869A (en)	1998-03-11	An antihaemolytic liposomal preparation
AU667090B2 (en)	1996-03-07	Lecithin fractions and dilutions, methods for their preparation and pharmacological uses thereof
EP0933080A1 (de)	1999-08-04	Mittel zur behandlung oder der prävention der hyperlipömie